Oncoclinicas do Brasil (ONCO3) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Oncoclinicas do Brasil BRL 0.29, price BRL 1.22, upside -76.2%, quality 20 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Oncoclinicas do Brasil for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range R$0.5500 – R$19.24 · fair‑value band R$0.1900 – R$0.3500 · the R$1.22 price screens above the R$0.2900 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Oncoclinicas do Brasil in your weekly email
Every Wednesday you see whether Oncoclinicas do Brasil is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America.
Show more
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, chemotherapy, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder cancer, oncological, kidney cancer, gynecological, and testicular cancer. It also provides diagnostics services comprising pathological analysis, genetic testing, molecular journey, personalized medicine and individualized treatment, myelogram-bone marrow biopsy, and ONCO test-PDO. In addition, the company offers treatment support services, which include veinviewer, cryotherapy, integrative medicine, and DeLife, as well as hilotherapy, laser therapy, OC care line, OC precision medicine, OncoACCESS, survivorship, and telemedicine services. Oncoclínicas do Brasil Serviços Médicos S.A. was founded in 2010 and is headquartered in São Paulo, Brazil.
Stock analysis
Oncoclinicas do Brasil (ONCO3) currently trades at R$1.22, while our model-based Fair Value estimate is R$0.2900, implying the stock looks roughly 320.7% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of R$0.5400 per share, and 0 of the 3 models we run sit above the R$1.22 price.
Bear case: the Dividend Discount group reads lowest at R$0.3600, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: R$0.1900 (bear) to R$0.3500 (bull), the price of R$1.22 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Oncoclinicas do Brasil reported revenue of R$5.7B in FY2025 versus R$2.7B in FY2021, a compound +20.7%/yr. Reported net income was −R$3.6B in FY2025.
Key figures
Market cap R$954M (≈ $185M) · P/S ratio 0.18 · EPS (TTM) R$−4.34 · Dividend yield 3.9% · Net margin −63.1% · Return on equity −206% · Return on assets (EBIT) −3.7% · Operating margin −24.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and 122% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −76%, ONCO3 screens richer than that median.
Fair Value models
Bear R$0.1900Fair Value R$0.2900Bull R$0.3500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Start year 2020 (pandemic). Over 10 years: +28.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.6% (2020) → −43.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score21 · Bottom 25%
Fair Value upside−76% · Bottom 25%
Profitability
Return on assets−12% · Bottom 25%
Net margin (TTM)−71% · Bottom 25%
Operating margin (TTM)−24% · Bottom 25%
Growth and dividend
Revenue growth−22% · Bottom 25%
Dividend yield (TTM)3.9% · Above median
Balance sheet
Debt / equity0.12× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/B0.21× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.03× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 31
HEALTH (low debt)94· sector 89
DIVIDEND (yield)77· sector 43
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oncoclinicas do Brasil Fair Value". https://www.fairvalue-calculator.com/stock/ONCO3
Frequently asked questions
Is Oncoclinicas do Brasil (ONCO3) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of R$0.2900 versus a price of R$1.22, about −76% upside (overvalued).
What is the fair value of ONCO3?
Our model-based fair value for Oncoclinicas do Brasil is R$0.2900 (as of Sep 24, 2026), built from audited fundamentals. The current price: R$1.22.
What is the quality score of ONCO3?
Oncoclinicas do Brasil has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oncoclinicas do Brasil (ONCO3)?
Our model-based price target is the fair value of R$0.2900 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario R$0.1900, optimistic scenario R$0.3500. It is a calculation from audited fundamentals, not an analyst target.
What is the Oncoclinicas do Brasil stock forecast for 2026?
Our models put fair value at R$0.2900, about −76% upside versus a price of R$1.22 (overvalued). Cautious scenario R$0.1900, optimistic scenario R$0.3500. The calculation is refreshed regularly with new filings.
What is the revenue of Oncoclinicas do Brasil (ONCO3)?
Oncoclinicas do Brasil reported trailing-twelve-month revenue of about R$5.4B (latest available figure, as of Sep 24, 2026).
Does Oncoclinicas do Brasil pay a dividend?
Oncoclinicas do Brasil currently shows a dividend yield of about 3.85% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Oncoclinicas do Brasil (ONCO3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oncoclinicas do Brasil it is R$0.2900 per share (as of Sep 24, 2026), against a price of R$1.22. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Oncoclinicas do Brasil stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ONCO3 trades above its calculated fair value: price R$1.22, fair value R$0.2900, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONCO3?
No. The price is what the market pays today (R$1.22); the fair value is what the company's own numbers justify (R$0.2900). For Oncoclinicas do Brasil the two are R$0.9300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oncoclinicas do Brasil worth?
The market values Oncoclinicas do Brasil at about R$954M (market capitalisation, as of Sep 24, 2026). Per share that is R$1.22; our models calculate a fair value of R$0.2900 per share.
What do the bullish and bearish scenarios say about ONCO3?
Our models span a range for Oncoclinicas do Brasil: cautious scenario R$0.1900, base R$0.2900, optimistic R$0.3500 per share (as of Sep 24, 2026, price R$1.22). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oncoclinicas do Brasil (ONCO3)?
Balance-sheet figures for Oncoclinicas do Brasil (as of Sep 24, 2026): return on equity −205.9%, debt of 0.12 per unit of equity. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is ONCO3 from its 52-week high?
Oncoclinicas do Brasil trades at R$1.22, about 66% below its 52-week high of R$3.58 and 122% above the low of R$0.5500 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of R$0.2900 is for.
Which stocks are comparable to Oncoclinicas do Brasil?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oncoclinicas do Brasil stock attractive at the current price?
The data as of Sep 24, 2026: price R$1.22, calculated fair value R$0.2900 (−76%), Quality Score 20/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONCO3 calculated?
We run Oncoclinicas do Brasil through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$0.2900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Oncoclinicas do Brasil itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oncoclinicas do Brasil (ONCO3)?
The closing price on Sep 23, 2026 was R$1.22. Our model-based fair value is R$0.2900, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oncoclinicas do Brasil right now?
The price sits above even our optimistic bull case (R$0.3500). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (R$0.1900 to R$0.3500) leaves room in how you read the outcome.
Key figures of Oncoclinicas do Brasil
How large is the market capitalisation of Oncoclinicas do Brasil (ONCO3)?
The market capitalisation of Oncoclinicas do Brasil is R$954M (≈ $185M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oncoclinicas do Brasil (ONCO3)?
The price-to-sales ratio of Oncoclinicas do Brasil is 0.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oncoclinicas do Brasil (ONCO3)?
Earnings per share at Oncoclinicas do Brasil are R$−4.34. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Oncoclinicas do Brasil (ONCO3)?
The dividend yield of Oncoclinicas do Brasil is 3.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Oncoclinicas do Brasil (ONCO3)?
The net margin of Oncoclinicas do Brasil is −63.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oncoclinicas do Brasil (ONCO3)?
The return on equity (ROE) of Oncoclinicas do Brasil is −206% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oncoclinicas do Brasil (ONCO3)?
On an EBIT basis the return on assets of Oncoclinicas do Brasil is −3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oncoclinicas do Brasil (ONCO3)?
The operating margin of Oncoclinicas do Brasil is −24.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oncoclinicas do Brasil (ONCO3)?
Revenue at Oncoclinicas do Brasil is growing −22.3% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oncoclinicas do Brasil (ONCO3)?
Earnings per share at Oncoclinicas do Brasil are growing −85.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Oncoclinicas do Brasil (ONCO3) generate?
The free cash flow of Oncoclinicas do Brasil is −R$287M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Oncoclinicas do Brasil (ONCO3) carry?
The net debt of Oncoclinicas do Brasil is R$3.3B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Oncoclinicas do Brasil in the live analysis
One click puts Oncoclinicas do Brasil on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
